Research programme: immunotherapeutic oligonucleotides - Alnylam/TekmiraAlternative Names: Immune stimulatory oligonucleotides - Alnylam/Tekmira
Latest Information Update: 04 May 2011
At a glance
- Originator Tekmira Pharmaceuticals Corporation
- Class Oligonucleotides
- Mechanism of Action Immunostimulants
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Discontinued Immunological disorders
Most Recent Events
- 04 May 2011 No development reported - Preclinical for Immunological disorders in USA (unspecified route)
- 10 Jan 2007 Preclinical trials in Immunological disorders in USA (unspecified route)